Abstract:Abstract Introduction: Thwarting metastasis is widely regarded as the “holy-grail” in the treatment of cancer. Despite epigenetic alterations being a major causal factor in promoting tumorigenesis, relatively little is known about key epigenetic events that drive breast cancer lung metastasis. Additionally, the molecular mechanism(s) by which the loss of SWI/SNF complex subunits-like Bromodomain-7 (BRD7)- induces incipient breast cancer cells to metastasize in the lung remains to be elucidated. Methods: We established a novel in vivo screening platform which enabled the identification of specific epigenetic entities that regulate metastatic reactivation. RNA-seq enabled the identification of the differential gene expression/signaling pathway profiles that govern metastatic reactivation upon loss of BRD7. Furthermore, tumor spheres and migration/invasion assays were performed. To decipher the modifications in the chromatin accessibility upon loss of BRD7, ChIP-seq and ATAC-seq were conducted. A magnetic bead-based Luminex cytokine assay informed us about the regulation of cytokines upon loss-of-BRD7. In vivo experiments were performed in the 4TO7-TGL and D2A1-d dormancy models and the NSG immunodeficient mice. FACS immune-phenotyping coupled with scRNA-seq was performed to comprehend the changes in the tumor immune microenvironment upon loss of BRD7. Results: The in vivo loss-of-function epigenetic screen revealed that loss of BRD7 led to breast cancer lung metastasis. Interestingly, RNA-seq revealed that BRD7 knockout promotes the expression of genes involved in inflammation, hypoxia and EMT. Intriguingly, the top signatures enriched in BRD7-silenced cells were IL6-JAK-STAT3 signaling and TNF-α signaling. Further, ATAC-seq and ChIP-seq experiments indicated that inactivation of BRD7 causes an increased chromatin accessibility at enhancer sites that were enriched for interferon-regulated immune response elements. Additionally, we found that BRD7-inactivation induces expression of pre-metastatic cytokines such as IL6, IL33, and CXCL12. Finally, the loss of BRD7 led to the up-regulation of the tumor-promoting neutrophils and CD8+ T exhausted cells while down-regulating the tumor-suppressive M1 macrophages, CD8+ Teff and Tmemory cells and the dendritic cell population in vivo. Conclusion: Our novel genomic screening platform shall enable the identification of specific genes that mediate breast cancer lung metastasis. Additionally, our findings that BRD7 is a suppressor of breast cancer lung metastasis, and a predictive cancer biomarker could have major implications in the formulation of myriad chemo-therapeutic strategies for metastatic cancers. Taken together, we strongly anticipate that our study will bring forth a paradigm shift in our understanding of how epigenetic regulators, like BRD7, mechanistically regulate breast cancer lung metastasis. Citation Format: Jayanta Mondal, Junfeng Zhang, Filippo Giancotti, Jason Huse. Loss of bromodomain-7 (BRD7) promotes breast cancer lung metastasis by reprogramming the tumor immune microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1294.

BRD7, a Novel Bromodomain Gene, Inhibits G1–S Progression by Transcriptionally Regulating Some Important Molecules Involved in Ras/mek/erk and Rb/E2F Pathways

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53

miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma

JQ1: a novel potential therapeutic target.

Growth Suppression of Nasopharyngeal Carcinoma Cell Through Transfection of BRD7 Gene

Prognostic Relevance of BRD7 Expression in Colorectal Carcinoma

Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4.

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer

BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

Bromodomain-containing protein 9 activates proliferation and epithelial-mesenchymal transition of colorectal cancer via the estrogen pathway in vivo and in vitro

LARP7 is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis

BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10

Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma

BRD9 is an Essential Regulator of Glycolysis That Creates an Epigenetic Vulnerability in Colon Adenocarcinoma

Abstract 1294: Loss of bromodomain-7 (BRD7) promotes breast cancer lung metastasis by reprogramming the tumor immune microenvironment

Ceap/BLOS2 interacts with BRD7 and selectively inhibits its transcription-suppressing effect on cellular proliferation-associated genes.